{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2021"],"condition":["Colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2707319"],"location":["China"],"study_start_month":["7"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"First-line treatment of mCapOX plus cetuximab versus mFOLFOX6 plus cetuximab for metastatic left-sided CRC patients with wild-type RAS/BRAF genes: a multicenter, randomised, phase 2 study","description":"Interventions: Experimental groupA:mCapOX+ Cetuximab;Experimental groupB:mFOLFOX6+ Cetuximab\nPrimary outcome(s): Progression free survival;Progression free survival\nStudy Design: Parallel","dates":{"creation":"2021-07-15"},"accession":"2707319","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2100047220"]}}